N/A N=78 Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes
Idiopathic Macular Hole
Primary: Visual Acuity (ETDRS Letters) — 74.9; 72.4; 72.2 Visual acuity in letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Effects of Pneumatic Vitreolysis on Macular Hole
Vitreomacular Traction (VMT) · Full-thickness Macular Holes (MH)
Primary: Proportion of Eyes With Macular Hole Closure of Inner Retinal Layers Without Rescue Vitrectomy — 10 Eyes
Phase 3 N=220 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Vitreomacular Adhesion Including Macular Hole
Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
Phase 3 N=326 Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.
Vitreomacular Adhesion
Primary: Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 — 25.3; 6.2 percentage of participants — p=<0.001
N/A N=19 Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
Macular Degeneration · Retinal Drusen
Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3
N/A N=33 Efficacy of Acupuncture in Macular Diseases
Age-related Macular Degeneration · Stargardt Disease · Macular Dystrophy
Primary: Change on Visual Acuity (VA) of the Treated Eyes From Baseline to the End of the Study — 36; 16; 4 Eyes
Phase 2 N=100 Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Exudative Age-Related Macular Degeneration · Focal Vitreomacular Adhesion
Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262
Phase 3 N=172 A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
Symptomatic Vitreomacular Adhesion
Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects
N/A N=9 Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
Low Vision · Age Related Macular Degeneration
Primary: Tilt of the PCIOL and IOPCL MAG Complex — 9; 9 Eyes
Phase 2 N=11 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Geographic Atrophy · Age-Related Macular Degeneration · AMD
Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters
Phase 4 N=44 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
Retinal Degenerations
Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants
Phase 4 N=46 Study for Recalcitrant Age Related Macular Degeneration
Age Related Macular Degeneration
Primary: The Number of Patients With no Fluid on OCT — 10 participants
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
N/A N=100 Evaluation of Retinal Microvascular Change That May Develop in After Open Globe Injury
Eye Injury Trauma
Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns
N/A N=87 Evaluation of Vitrectomy for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Visual Acuity — 52 Units on a scale
Phase 4 N=26 The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
Wet Macular Degeneration
Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2
Phase 2 N=5 Sirolimus to Treat Diabetic Macular Edema
Diabetic Retinopathy
Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters
N/A N=36 A Multi-Center Study of Reading Rehabilitation in Macular Disease
Age Related Maculopathy · Retinal Degeneration
Primary: Sentence Reading — 58.9; 50.5; 86.2; 49.1 Words per Minute (wpm)
Phase 2 N=320 A Study of NGM621 in Participants With Geographic Atrophy
Geographic Atrophy
Primary: The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area — 2.243; 2.237; 2.393 mm^2 per year — p=0.4345
Phase 2 N=105 Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema
Macular Edema
Primary: Change From Baseline in Central Subfield Foveal Thickness (CSFT) at Week 12 — -6.19; 10.26 Micrometre [μm] — p=0.3199
Phase 1 N=14 A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Rhegmatogenous Retinal Detachment - Macula Off
Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants
Phase 3 N=120 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
Macular Telangiectasia Type 2 (MacTel)
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.075; 0.166 mm^2 — p=<0.0001
Phase 2 N=57 Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
Macular Degeneration
Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…
Phase 4 N=52 Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Vitreomacular Traction · Vitreomacular Adhesion
Primary: Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence…
Phase 1 N=40 An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) — 0.810; 0.526; 2.762; 1.833 letters
Phase 2 N=22 Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion
Diabetic Macular Edema
Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…
Phase 3 N=119 A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
Macular Telangiectasia Type 2
Primary: The Rate of Change in the Area of EZ Area of Loss From Baseline Through Month 24 — 0.111; 0.160 mm^2 — p=0.0186